Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358751 | 0.94 | KMT2A (0.67) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL11200758 | 0.91 | ALDH1A1 (0.62) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL16695904 | 0.91 | HTR2A (0.56) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| Alanine SCHEMBL27705533 | 0.89 | ALDH1A1 (0.57) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL11116815 | 0.88 | MEN1 (0.72) | KMT2ALMNAALDH1A1RAB9AHTT | |
| SCHEMBL11684706 | 0.87 | ALDH1A1 (0.63) | KMT2AALDH1A1RAB9AALOX5HTT | |
| SCHEMBL9385826 | 0.86 | ALDH1A1 (0.66) | KMT2AALDH1A1RAB9AHTTMEN1 | |
| SCHEMBL5335470 | 0.86 | KMT2A (0.60) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL12856432 | 0.86 | ALOX5 (0.61) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL9385816 | 0.86 | ALDH1A1 (0.66) | KMT2AALDH1A1RAB9AHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5977065-A | FROM A PRODRUG | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-11-02 | — | — | US | claimed |
| US-20250391519-A1 | CHEMICAL SYNTHESIS PLATFORM | UNIV GLASGOW COURT (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4548355-A1 | CHEMICAL SYNTHESIS PLATFORM | The University Court Of The University Of Glasgow (GB) | 2025-05-07 | — | — | EP | disclosed |
| CN-116751137-B | Method for preparing chloro aromatic compound by photo-induced nitroarene denitration chlorination | 华中师范大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-116870016-B | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117412981-A | Phosphine oxide derivative and preparation method and application thereof | 希格生科（深圳）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| WO-2024003151-A1 | CHEMICAL SYNTHESIS PLATFORM | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2024-01-04 | — | — | WO | disclosed |
| US-11802108-B2 | Compounds for the modulation of cyclophilins function | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2023-10-31 | — | — | US | disclosed |
| CN-116870016-A | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-110698459-B | 1-phenyl-2-pyridylalkyl alcohol derivatives as phosphodiesterase inhibitors | 奇斯药制品公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-0672034-A1 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995012678-A2 | IMPROVEMENTS RELATING TO CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
| EP-0542837-B1 | PROPYLAMINE DERIVATIVES | NORGINE LTD (GB) | 1995-05-10 | — | — | EP | disclosed |
| EP-0638123-A1 | BACTERIAL NITROREDUCTASE FOR THE REDUCTION OF CB 1954 AND ANALOGUES THEREOF TO A CYTOTOXIC FORM | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-02-15 | — | — | EP | disclosed |
| WO-1995002420-A2 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994012478-A1 | BENZIMIDAZOLE COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-09 | — | — | WO | disclosed |
| EP-0542837-A1 | PROPYLAMINE DERIVATIVES. | NORGINE LTD (GB) | 1993-05-26 | — | — | EP | disclosed |
| EP-0540263-A1 | Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-05-05 | — | — | EP | disclosed |
| WO-1993008288-A1 | BACTERIAL NITROREDUCTASE FOR THE REDUCTION OF CB 1954 AND ANALOGUES THEREOF TO A CYTOTOXIC FORM | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-04-29 | — | — | WO | disclosed |
| WO-1992002488-A1 | PROPYLAMINE DERIVATIVES | NORGINE LIMITED (GB) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802108-B2 | Compounds for the modulation of cyclophilins function | CBR1, CBR3, PPIC | KMT2A 4338/4885SLC6A2 1852/4885SLC6A3 1529/4885 |
| US-20250391519-A1 | CHEMICAL SYNTHESIS PLATFORM | SET, CBS, COASY | KMT2A 1049/4885SLC6A2 1809/4885SLC6A3 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.